Responses
Clinical/translational cancer immunotherapy
Original research
Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.